If you or someone you love has non-small cell lung cancer (NSCLC), you may have heard about immunotherapy drugs called immune checkpoint inhibitors. These treatments help your immune system fight cancer. Recently, doctors have started giving these drugs before surgery to shrink tumors and improve outcomes. But is it safe to operate after immunotherapy? A new analysis of 2,691 patients offers some answers.
Researchers combined data from multiple studies to look at what happens when people with resectable NSCLC (cancer that can be surgically removed) receive immunotherapy before or around the time of surgery. They wanted to know about surgical complications, delays, and how often surgery could be done with minimally invasive techniques.
Here is what they found. Serious complications during surgery were rare, happening in only about 3 out of every 100 patients. After surgery, about 27 out of 100 patients had some complication, which is similar to what is seen with chemotherapy alone. Death after surgery was very uncommon, occurring in about 1 out of 100 patients. About 10% of patients needed a pneumonectomy (removal of an entire lung), which is a more extensive surgery. Minimally invasive surgery (using small incisions) was used in 47% of cases, but about 20% of those had to be converted to open surgery. Surgical delays happened in 9% of patients, and about 9% ended up not having surgery at all.
These numbers tell us that surgery after immunotherapy is generally safe, but it is not without challenges. The conversion rate to open surgery is higher than what is typically seen without immunotherapy, and the rate of pneumonectomy is notable. This means that patients need to be treated by experienced surgeons and teams who can handle these complexities.
It is important to remember that this is a pooled analysis of many studies, not a single large trial. The studies included different types of immunotherapy and chemotherapy combinations, and the patients were carefully selected. So these results may not apply to everyone. Also, the analysis did not report on long-term outcomes like cancer recurrence or survival.
For now, the takeaway is that immunotherapy before lung cancer surgery is a reasonable option for appropriate patients, but it requires careful planning and a skilled surgical team. If you are considering this approach, talk to your doctor about the risks and benefits specific to your situation.
